BridgeBio Oncology Therapeutics (BBOT)
NASDAQ:BBOT
Want to see BBOT full AI Analyst Report?
BBOT Stock Chart & Stats
$12.59
--
Market closed
$12.59
--
Day’s Range― - ―
52-Week Range$8.08 - $14.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)344.97K
Market Cap
$757.11M
Enterprise Value$338.97M
Total Cash (Recent Filing)$425.46M
Total Debt (Recent Filing)$2.77M
Price to Earnings (P/E)―
Beta0.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding80,032,820
10 Day Avg. Volume232,276
30 Day Avg. Volume344,973
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.95
Price to Sales (P/S)0.00
P/FCF Ratio-3.41
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.75K
Enterprise Value/Ebitda-2.33
Forecast
1Y Price Target
$25.57Price Target Upside103.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash Runway And Pipeline CatalystsSubstantial cash reserves combined with multiple planned clinical readouts and combination studies create several potential value inflection points as development milestones are achieved.
Combination Potential With ImmunotherapyTumor responses seen with BBO-8520 plus pembrolizumab across different PD-L1 levels, including first-line patients, indicate the drug may pair effectively with standard immunotherapy and expand the addressable patient population.
Safety ProfileBBO-8520's lack of observed liver enzyme elevations and absence of heart rhythm prolongation in trials supports a favorable safety profile that may enable broader combination use and reduce treatment discontinuations.
Bears Say
Clinical And Regulatory RiskClinical setbacks, failure to advance assets into pivotal trials, or regulatory rejection may severely limit approval prospects and pressure the stock through missed milestones.
Immature Clinical DataApparent tolerability and efficacy advantages remain unproven until larger, more mature datasets are available, leaving investor expectations vulnerable to negative surprises from subsequent readouts.
Tolerability Skepticism Among Key Opinion LeadersSkepticism from key opinion leaders about the tolerability of earlier inhibitor classes means durable safety in combination settings must be demonstrated to secure clinician support and adoption.
BridgeBio Oncology Therapeutics News
BBOT FAQ
What was BridgeBio Oncology Therapeutics’s price range in the past 12 months?
BridgeBio Oncology Therapeutics lowest stock price was $8.08 and its highest was $14.87 in the past 12 months.
What is BridgeBio Oncology Therapeutics’s market cap?
BridgeBio Oncology Therapeutics’s market cap is $757.11M.
When is BridgeBio Oncology Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BridgeBio Oncology Therapeutics’s earnings last quarter?
Currently, no data Available
Is BridgeBio Oncology Therapeutics overvalued?
According to Wall Street analysts BridgeBio Oncology Therapeutics’s price is currently Undervalued.
Does BridgeBio Oncology Therapeutics pay dividends?
BridgeBio Oncology Therapeutics does not currently pay dividends.
What is BridgeBio Oncology Therapeutics’s EPS estimate?
BridgeBio Oncology Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BridgeBio Oncology Therapeutics have?
BridgeBio Oncology Therapeutics has 80,032,820 shares outstanding.
What happened to BridgeBio Oncology Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BridgeBio Oncology Therapeutics?
Currently, no hedge funds are holding shares in BBOT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Oncology Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.57 (103.11% Upside)
$25.57 (103.11% Upside)
Crowd Wisdom
Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.62%
12-Months-Change
Fundamentals
Return on Equity
-65.52%
Trailing 12-Months
Asset Growth
130.98%
Trailing 12-Months
Company Description
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BBOT Stock 12 Month Forecast
Average Price Target
$25.57
▲(103.11% Upside)